Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. (October 2022)

• Record Type: Journal Article
• Authors: Franko, Jan; Yin, Jun; Adams, Richard A.; Zalcberg, John; Fiskum, Jack; Van Cutsem, Eric; Goldberg, Richard M.; Hurwitz, Herbert; Bokemeyer, Carsten; Kabbinavar, Fairooz; Curtis, Alexandra; Meyers, Jeffery; Chibaudel, Benoist; Yoshino, Takayuki; de Gramont, Aimery; Shi, Qian
• Is Part Of: European journal of cancer. Volume 174(2022)
• Page Start: 142
• Page End: 152
• Publication Date: 2022-10
• Subjects: Body mass index -- Colorectal cancer -- Performance status -- Early weight loss -- Peritoneal metastases; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.07.021
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Higher body mass index is associated with a higher incidence of colorectal cancer (CRC) but also with improved survival in metastatic CRC (mCRC). Whether weight change after mCRC diagnosis is associated with survival remains largely unknown. Methods: We analysed individual patient data for previously untreated patients enrolled in five phase 3 randomised trials conducted between 1998 and 2006. Weight measurements were prospectively collected at baseline and up to 59.4 months after diagnosis. We used stratified multivariable Cox models to assess the prognostic associations of weight loss with overall and progression-free survival, adjusting for other factors. The primary end-point was a difference in overall survival (OS) between populations with weight loss and stable or increasing weight. Findings: Data were available for 3504 patients. The median weight change at 3 months was −0.54% (IQR −3.9 … +1.5%). We identified a linear trend of increasing risk of death associated with progressive weight loss. Unstratified median OS was 20.5, 18.0, and 11.9 months (p < 0.001) for stable weight or gain, <5% weight loss, and ≥5% weight loss at 3 months, respectively. Weight loss was associated with a higher risk of death (<5% loss: aHR 1.18 [1.06–1.30], p < 0.002; ≥5% loss: aHR 1.87 [1.67–2.1], p < 0.001) as compared to stable or increasing weight at 3 months post-baseline (reference), while adjusting for age, sex, performance, and a number of metastatic sites. Interpretation: Patients losing weight during systemic therapy for metastatic colorectal cancer have significantly shorter OS. The degree of weight loss is proportional to the observed increased risk of death and remains evident among underweight, normal weight, and obese individuals. On-treatment weight change could be used as an intermediate end-point. Funding: The creation and management of the database containing the individual patient data from the original randomised trials is supported by the Aide et Recherche en Cancérologie Digestive Foundation. Highlights: Weight loss is proportional to the risk of death among mCRC patients. Weight loss ≥5% is associated with significantly shorter survival. Median overall survival was 20.5 months if there was no weight loss. Median overall survival was 11.9 months if ≥ 5% weight loss at 3 months.